echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > The FDA accepts applications for a new drug for Thermolotinib for the treatment of anemia in myelofibrosis

    The FDA accepts applications for a new drug for Thermolotinib for the treatment of anemia in myelofibrosis

    • Last Update: 2022-09-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Based on the results of the Phase 3 MOMENTUM trial, the FDA has accepted a new drug application


    According to a press release from drug developer GSK.


    Acceptance is based on the results of the Phase 3 MOMENTUM trial (NCT04173494), which evaluated the drug compared to danazole in a group of symptomatic patients previously treated with JAK inhibitors


    The results of this trial were presented


    At 24 weeks, 72.


    In terms of spleen response rate at 24 weeks, patients in the momelotinib group were reduced by 25% in 40.


    In the domelotinib and danazol groups, grade 3 or higher AE was observed in 53.


    Resources:

    1. US FDA accepts new drug application for GSK’s momelotinib for the treatment of myelofibrosis.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.